Is presensitization relevant to liver transplantation outcome?

Human Immunology

Volumn 63, Issue 9, 2002, Pages 742-750

  Bishara, Amal ^a,d   Brautbar, Chaim ^a,b   Eid, Ahmed ^c   Scherman, Leni ^a   Ilan, Yaron ^d   Safadi, Rifaat ^d  

^a Tissue Typing Unit   (Israel)

^b Tissue Typing Unit and Lautenberg Center for General and Tumor Immunology   (Israel)

^c Department of Surgery ^*  (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Crossmatch; ELISA; HLA antibodies; LAT M; Liver rejection

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; SENSITIZATION; TREATMENT OUTCOME;

ADULT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0036731831     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(02)00429-9     Document Type: Article

References (56)

1. Crossmatching in liver transplantation
2. Utility of pretransplant crossmatch and antibody screening for liver and cardiac transplantation
3. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells
4. The effect of HLA, lymphocytotoxic antibody status and crossmatch result on cardiac transplant survival
5. Successful liver transplantation from crossmatch-positive donors
6. Liver transplantation against T cell-positive warm crossmatches
7. Probable antibody mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient
8. The antibody crossmatch in liver transplantation
9. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors
10. Positive crossmatch in primary liver allografts under cyclosporin or FK506 therapy
11. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies
12. The flow cytometric crossmatch in liver transplantation
13. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection
14. Relevance of a positive crossmatch in liver transplantation
15. Influence of positive lymphocyte crossmatch and HLA matching on vanishing bile duct syndrome in human liver allografts
16. Positive pretransplant crossmatches predict early graft loss in liver allograft recipients
17. Chronic rejection after liver transplantation: A study of clinical histopathological and immunological features
18. HLA compatibility and liver transplant outcome: Improved patient survival by HLA and crossmatching
19. Positive IgG donor specific crossmatches are not associated with graft rejection or poor graft survival following liver transplantation: An assessment by cytotoxicity and flow cytometry
20. The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies
21. Evidence for an immune response to HLA class I in the vanishing bile duct syndrome after liver transplantation
22. Enzyme-linked immunoassay for anti-HLA antibodies: An alternative to panel studies by lymphocytotoxicity
23. A new micro-Elisa for anti-class I and class II antibody detection
24. Acute and chronic hepatic allograft rejection: Pathology and classification
25. Microdroplet testing for HLA-A,B,C and D antigens The Phillip Levine Award Lecture
26. High-resolution analysis of the human HLA-DR polymorphism by hybridization with sequence-specific oligonucleotide probes
27. Microdroplet assay of human serum cytotoxins
28. Nonparametric estimation from incomplete observations
29. Evaluation of survival data and two new rank order statistics arising in its consideration
30. A positive crossmatch in liver transplantation-no effect or inappropriate analysis? A prospective study
31. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts
32. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high grade cellular rejection in recipient of heart transplantation
33. Mechanisms of liver transplant rejection
34. Soluble HLA antigens in the circulation of liver graft recipients
35. Affinity purified HLA class I molecules specifically inhibit a human CTL line in vitro
36. Postoperative flow cytometry crossmatch in living donor liver transplantation: Clinical significance of humoral immunity in acute rejection
37. Cell-cell interaction in the antibody response
38. Alloimmunization, memory and the interpretation of crossmatch results for renal transplantation
39. The dynamic nature of the antibody repertoir
40. Human IgG xenoreactive antibodies mediate damage to porcine endothelial cells in vitro by both humoral and cellular mechanisms
41. High one-month liver graft failure rates in flow cytometry crossmatch-positive recipients
42. Significance of a positive crossmatch on outcome in human liver transplantation
43. Hepatic allograft rescue following arterial thrombosis
44. Low hematocrit reduces hepatic artery thrombosis after liver transplantation
45. Vascular complication after orthotopic liver transplantation
46. Prolonged preservation in University of Wisconsin solution associated with hepatic artery thrombosis after orthoptic liver transplantation
47. Signal transduction in lymphocyte activation through cross-linking of HLA class I molecules
48. Signal transduction via MHL class-I molecules in T cells
49. Anti-HLA antibodies ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosin phosphorylation, inosital phosphatase generation, and proliferation
50. Cardiac allograft vasculopathy: Preferential regulation of endothelial cell-derived mesenchymal growth factors in response to a donor-specific cell-mediated allogeneic response
51. Human coronary transplantation associated arteriosclerosis: Evidence for a chronic immune reaction to activated graft endothelial cells
52. HLA antigen expression on cultures human arterial endothelial cells
53. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases
54. Active proliferation of different cell types, including lymphocytes in human atherosclerotic plaques
55. Accelerated atherosclerosis in cardiac transplantation: Role of cytotoxic B-cell antibodies and hyperlipidemia